Soleno Therapeutics Inc (SLNO) — 10-Q Filings

10-Q Filings (6)

• SLNO Swings to Profit on VYKAT XR Launch, Cash Reserves Soar — Nov 4, 2025 Risk: medium
  Soleno Therapeutics Inc. (SLNO) reported a significant financial turnaround for the three months ended September 30, 2025, achieving a net income of $26.013 mil
• Solenos Net Loss Widens 18% Amid R&D Surge; $100M Offering Boosts Cash — Aug 6, 2025 Risk: high
  SOLENO THERAPEUTICS INC reported no revenue for the six months ended June 30, 2025, consistent with its clinical-stage status. The company incurred a net loss o
• Solen Therapeutics Files Q1 2025 10-Q — May 7, 2025 Risk: medium
  Solen Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Capnia, Inc., is involved in electromedical and elec
• Solen Therapeutics Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
  Solen Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Capnia, Inc., is incorporated in Delaware and he
• Solen Therapeutics Inc. Files Q2 2024 10-Q Report — Aug 7, 2024 Risk: medium
  Solen Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates. Key financial data
• Soleno Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  SOLENO THERAPEUTICS INC (SLNO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Soleno Therapeutics Inc. filed a 10-Q report for the period ending M

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX